Superworth

ImmunityBio EPS IBRX

Diluted earnings per share by quarter and over the last twelve months, from 2014.

Last 12 months, to Jun 30, 2026
−$0.97
Latest quarter, Q2 FY26
−$0.22
Fiscal year 2025
−$0.38

ImmunityBio's earnings per share was −$0.97 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$0.22.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$0.38n/a
FY2024−$0.62n/a
FY2023−$1.13n/a
FY2022−$1.05n/a
FY2021−$0.89n/a
FY2020−$0.71n/a
FY2019−$0.71n/a
FY2018−$1.22n/a
FY2017−$1.20n/a
FY2016−$1.47n/a
FY2015−$3.46n/a
FY2014−$0.87n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$0.22n/a−$0.97
Q1 FY26−$0.62n/a−$0.85
Q4 FY25−$0.06n/a−$0.38
Q3 FY25−$0.07n/a−$0.40
Q2 FY25−$0.10n/a−$0.47
Q1 FY25−$0.15n/a−$0.57
Q4 FY24−$0.08n/a−$0.62
Q3 FY24−$0.14n/a−$0.89
Q2 FY24−$0.20n/a−$0.94
Q1 FY24−$0.20n/a−$1.06
Q4 FY23−$0.35n/a−$1.13
Q3 FY23−$0.19n/a−$1.05

Against its peers

Companies in Biotechnology nearest ImmunityBio's size, closest first, today.

CompanyEPS, 12 monthsGrowth
IBRXImmunityBio−$0.97
KRYSKrystal Biotech$7.98+62% a year
RGENRepligen$0.73
TECHBIO-TECHNE$1.15+150% a year
HALOHalozyme Therapeutics$3.35−23% a year
NBIXNeurocrine Biosciences$6.82+102% a year
EXELExelixis$3.18+53% a year
INCYIncyte$7.85+78% a year
UTHRUnited Therapeutics$27.95+9% a year
ALNYAlnylam Pharmaceuticals$5.93
ADMAAdma Biologics$0.70−18% a year
Peer median$4.64

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on ImmunityBio

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.